NEW YORK (GenomeWeb News) – Roche today said that it has signed a co-marketing deal with UK pathology and molecular diagnostic lab Unilabs-IHS to provide Roche's cobas HPV test to women in the UK.
Unilabs will provide the test as a follow-up to traditional Pap cervical smears and, upon request, as a primary screen for cervical pre-cancer.
The cobas HPV test identifies genotypes 16 and 18, the highest risk types associated with the development of cervical cancer and its precursor lesions, as well as 12 other high-risk HPV types. The assay runs on Roche's cobas 4800 system and was launched in 2009 in countries that accept the CE Mark. The HPV assay also was cleared for marketing by the US Food and Drug Administration in April 2011.
"Given the clear benefits of this technology to patients as well as the NHS, we look forward to seeing the technology's timely introduction at the primary screening stage, across the country via the national cervical screening programme — promising a better deal for women and a more efficient approach to cervical screening," Paul Eros, director of molecular diagnostics at Roche, said in a statement.